Surgical treatment of breast cancer in Norway 2003–2018

Skjerven, Helle; Danielsen, Anders Skyrud; Schlichting, Ellen; Sahlberg, Kristine Kleivi; Hofvind, Solveig

doi:10.4045/tidsskr.20.0090

Cited by 2 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a temporary decline in BCT for DCIS during the period from 2005 to 2009. This decline has also been reported in other studies, for DCIS and for invasive breast cancer [29, 34, 35]. The trend could be attributed to the interpretation of the Early Breast Cancer Trialists’ Group review published in 2005 which suggested an increased incidence of local recurrences and a higher breast cancer mortality in women treated with BCT [36].…”

Section: Discussion/conclusionsupporting

confidence: 77%

“…Breast and endocrine surgery became a surgical subspecialty in Norway 2008. This, together with the implementation of BreastScreen Norway during the period from 1996 to 2005, the number of hospitals involved in breast diagnostics, and treatment, was reduced from 64 to about 20 [28, 29]. This might be of influence for the increased use of BCT during the study period.…”

Section: Discussion/conclusionmentioning

confidence: 99%

“…The trend could be attributed to the interpretation of the Early Breast Cancer Trialists’ Group review published in 2005 which suggested an increased incidence of local recurrences and a higher breast cancer mortality in women treated with BCT [36]. Later studies disproved these findings [34], after which the rates of BCT has increased steadily [29]. In our study, 84.5% of women diagnosed with DCIS had BCT in 2018, which is close to the European Society of Breast Cancer Specialists (EUSOMA) target of 90% for noninvasive breast cancer smaller than 20 mm [14].…”

Section: Discussion/conclusionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018

et al. 2022

Self Cite

View full text Add to dashboard Cite

Introduction: The incidence of ductal carcinoma in situ (DCIS) has increased after implementation of mammographic screening. The lesion represents management challenges due to its undetermined growth pattern. We aimed to explore treatment of women aged 48-71 diagnosed with DCIS between 1995 and 2018, by detection mode and histopathological characteristics. Material and methods: Data on surgical treatment and radiation therapy (RT) of 4995 women diagnosed with DCIS were retrieved from the Cancer Registry of Norway. We described the percentage and frequency of breast conserving treatment (BCT) for participants in Breast Screen Norway (screen-detected) and non-participants. We estimated the relative risk (RR) of BCT, using log-binomial regression models. Results: Use of BCT increased from about 40% in 1995 to 85% in 2018. Use of BCT was more common among older than younger women more commonly used for screen-detected versus tumors detected outside the screening program. Nine out of ten women with tumors ≤10mm were treated with BCT, two out of ten with tumors >50mm. RT was given to 89.3% of the women with tumors ≤10 mm, 34.1% of those with tumors classified as van Nuys’ grade 1 and <10mm, and 96.0% of the tumors >50mm. Use of BCT was less common for tumors >50mm compared to <10mm (RR adjusted for age, detection mode, van Nuys’ grade, and localization: 0.26, 95% CI: 0.19-0.36). Conclusion: BCT was increasingly used among women diagnosed with DCIS in Norway during the period from 1995 to 2018, particularly for screen-detected, small lesions with low van Nuys’ grade.

show abstract

Section: Discussion/conclusionsupporting

confidence: 77%

Section: Discussion/conclusionmentioning

confidence: 99%

Section: Discussion/conclusionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the most important task in the field of breast cancer prevention is to perform mammography in as many women as possible due to the fact that early diagnosis of cancer allows for effective treatment and thus significantly reduces the number of deaths due to breast cancer among women aged 50-69. [1,21,22,23,24,25,26].…”

Section: Resultsmentioning

confidence: 99%

Epidemiology of breast cancer in women in Norway

Pałac,

Mielnik,

Cipora

2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction. Breast cancer in women in Norway currently accounts for 23% of all cancer cases and is also the most common cause of death in this population. Thanks to the availability of preventive tests and the implementation of tests, many cases of the disease are diagnosed at an early stage, which has a positive impact on the prognosis. The introduction of new technologies and treatment methods in oncology has given many women a chance for longer survival and even complete recovery. The aim of the study was to present the epidemiological situation of women with breast cancer in Norway and to identify factors that may be important for the incidence, duration of survival and mortality due to this cancer. Material and methods. The work uses a review and analysis of the literature from the Norwegian online database Kreftregisteret Cancer in Norway (from 2019-2022) and a review of data published by: Norwegian Ministry of Health and Welfare and Statistics Norway. Results. Breast cancer in Norway is the most common cause of death in women under 65 years of age. In 2022, 4,197 new cases were recorded, i.e. more than in previous years, and the average age of women at diagnosis was 62 years. The incidence rate of breast cancer in the female population aged 50–69 was also higher and clearly associated with the more frequent use of hormonal treatment during menopause. The effects of treatment of this cancer in Norway are satisfactory, because nine out of ten women diagnosed with breast cancer survive 5 years after diagnosis. Conclusions. Breast cancer among women in Norway is still a serious health and social problem, but the functioning of the health care system and the attitude of women themselves allow for satisfactory treatment results. Evidence of significant progress in the diagnosis and treatment of women diagnosed with breast cancer is the fact that over 90% of patients with this cancer can be considered cured.

show abstract

Surgical treatment of breast cancer in Norway 2003–2018

Cited by 2 publications

References 13 publications

Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018

Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018

Epidemiology of breast cancer in women in Norway

Contact Info

Product

Resources

About